Literature DB >> 22796734

Volume is not the only key to hypertension control in dialysis patients.

Aghogho Odudu1, Christopher McIntyre.   

Abstract

There is a widely held belief that hypervolaemia due to excess intake or inadequate removal of salt and water is the principal cause of hypertension in dialysis patients. The risk of failing to consider additional pathophysiological elements is that inadequate or inappropriate therapeutic strategies may be adopted. This review aims to highlight multiple alternative mechanisms for hypertension in this setting along with the risks of probing for normotension by empirical dry weight reduction if dry weight is imprecisely defined.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22796734     DOI: 10.1159/000339099

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  4 in total

1.  Whole-body single-frequency bioimpedance analysis in pediatric hemodialysis patients.

Authors:  Gia Oh; Cynthia Wong; Brandy Begin; Kari Salsbery; Scott Sutherland; Abanti Chaudhuri
Journal:  Pediatr Nephrol       Date:  2014-02-26       Impact factor: 3.714

2.  Bioimpedance-guided fluid management in hemodialysis patients.

Authors:  Ulrich Moissl; Marta Arias-Guillén; Peter Wabel; Néstor Fontseré; Montserrat Carrera; José Maria Campistol; Francisco Maduell
Journal:  Clin J Am Soc Nephrol       Date:  2013-08-15       Impact factor: 8.237

3.  Commentary on: The effect of allopurinol on lowering blood pressure in hemodialysis patients with hyperuricemia.

Authors:  Hamid Nasri
Journal:  J Res Med Sci       Date:  2013-05       Impact factor: 1.852

4.  Relationship between doses of antihypertensive drugs and left ventricular mass index changes in hemodialysis patients in a Japanese cohort.

Authors:  Fumiya Kitamura; Makoto Yamaguchi; Takayuki Katsuno; Hironobu Nobata; Shiho Iwagaitsu; Hirokazu Sugiyama; Hiroshi Kinashi; Shogo Banno; Masahiko Ando; Yoko Kubo; Yasumasa Kawade; Iwashima Shigejiro; Yutaka Ito; Takuji Ishimoto; Yasuhiko Ito
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.